Previous analysis has been performed on the daily number of cases, deaths, infected people, and people who were exposed to the virus, all of them in a timeline of 550 days. Moreover, it has made the fitting of infection spread detailing the most efficient and optimal methods with lower propagation error and the presence of statistical biases. Finally, four different prevention scenarios were proposed to evaluate the ratio of each one of the parameters related to the disease.

Surges that have been observed at different periods in the number of COVID-19 cases are associated with the emergence of multiple SARS-CoV-2 (Severe Acute Respiratory Virus) variants. The design of methods to support laboratory detection are crucial in the monitoring of these variants. Hence, in this paper, we develop a semi-automated method to design both forward and reverse primer sets to detect SARS-CoV-2 variants. To proceed, we train deep Convolution Neural Networks (CNNs) to classify labelled SARS-CoV-2 variants and identify partial genomic features needed for the forward and reverse Polymerase Chain Reaction (PCR) primer design. Our proposed approach supplements existing ones while promoting the emerging concept of neural network assisted primer design for PCR. Our CNN model was trained using a database of SARS-CoV-2 full-length genomes from GISAID and tested on a separate dataset from NCBI, with 98\% accuracy for the classification of variants. This result is based on the development of three different methods of feature extraction, and the selected primer sequences for each SARS-CoV-2 variant detection (except Omicron) were present in more than 95 \% of sequences in an independent set of 5000 same variant sequences, and below 5 \% in other independent datasets with 5000 sequences of each variant. In total, we obtain 22 forward and reverse primer pairs with flexible length sizes (18-25 base pairs) with an expected amplicon length ranging between 42 and 3322 nucleotides. Besides the feature appearance, in-silico primer checks confirmed that the identified primer pairs are suitable for accurate SARS-CoV-2 variant detection by means of PCR tests.

The virus's spike proteins (purple) are a key antibody target, with some antibodies attaching to the top (darker purple) and others to the stem (paler zone). A new study shows that it is possible to use the genetic sequences of a person's antibodies to predict what pathogens those antibodies will target. "Our research is in a very early stage, but this proof-of-concept study shows that we can use machine learning to connect the sequence of an antibody to its function," said Nicholas Wu, a professor of biochemistry at the University of Illinois Urbana-Champaign who led the research with biochemistry PhD student Yiquan Wang; and Meng Yuan, a staff scientist at Scripps Research in La Jolla, California. With enough data, scientists should be able to predict not only the virus an antibody will attack, but which features on the pathogen the antibody binds to, Wu said. For example, an antibody may attach to different parts of the spike protein on the SARS-CoV-2 virus.

Covid-19 can cause lasting cognitive and mental health issues, including brain fog, fatigue and even post-traumatic stress disorder. To better understand the scale of the problem, researchers at the University of Cambridge analysed 46 people who were hospitalised due to the infection between March and July 2020. The participants underwent cognitive tests on average six months after their initial illness. These results were compared against those of more than 66,000 people from the general population. Those hospitalised with covid-19 scored worse on verbal analogical reasoning tests, which assess an individual's ability to recognise relationships between ideas and think methodically. They also recorded slower processing speeds. Previous studies suggest glucose is less efficiently used by the part of the brain responsible for attention, complex problem-solving and working memory after covid-19. Scores and reaction speeds improved over time, however, any recovery was gradual at best, according to the researchers. This cognitive impairment probably has multiple causes, including inadequate blood supply to the brain, blood vessel blockage and microscopic bleeds caused by SARS-CoV-2 virus, as well as damage triggered by an overactive immune system, they added. "Around 40,000 people have been through intensive care with covid-19 in England alone and many more will have been very sick, but not admitted to hospital," Adam Hampshire at Imperial College London said in a statement. "This means there is a large number of people out there still experiencing problems with cognition many months later." The biological mechanism behind a rare and severe covid-19 response seen in some children may have been uncovered by researchers at the Murdoch Children's Research Institute in Melbourne, Australia. Doctors have so far been unable to identify why some children develop multisystem inflammatory syndrome (MIS) in response to covid-19, which can cause symptoms such as fever, abdominal pain and heart disease.

A new study shows that it is possible to use the genetic sequences of a person's antibodies to predict what pathogens those antibodies will target. "Our research is in a very early stage, but this proof-of-concept study shows that we can use machine learning to connect the sequence of an antibody to its function," said Nicholas Wu, a professor of biochemistry at the University of Illinois Urbana-Champaign who led the research with U. of I. biochemistry Ph.D. student Yiquan Wang; and Meng Yuan, a staff scientist at Scripps Research in La Jolla, California. With enough data, scientists should be able to predict not only the virus an antibody will attack, but which features on the pathogen the antibody binds to, Wu said. For example, an antibody may attach to different parts of the spike protein on the SARS-CoV-2 virus. Knowing this will allow scientists to predict the strength of a person's immune defense, as some targets of a pathogen are more vulnerable than others.

Using a machine learning model, scientists could predict not only the virus an antibody will attack, but which features on the pathogen the antibody binds to. A new study by University of Illinois Urbana-Champaign, US has shown that by using machine learning, it is possible to use the genetic sequences of a person's antibodies to predict what pathogens those antibodies will target. Recently published in Immunity, the new approach successfully differentiates between antibodies against influenza and those attacking SARS-CoV-2. The virus's spike proteins (purple) are a key antibody target, with some antibodies attaching to the top (darker purple) and others to the stem (paler zone) [Credit: Graphic by Yiquan Wang}. "Our research is in a very early stage, but this proof-of-concept study shows that we can use machine learning to connect the sequence of an antibody to its function," said Professor Nicholas Wu.

A new study shows that it is possible to use the genetic sequences of a person's antibodies to predict what pathogens those antibodies will target. "Our research is in a very early stage, but this proof-of-concept study shows that we can use machine learning to connect the sequence of an antibody to its function," said Nicholas Wu, a professor of biochemistry at the University of Illinois Urbana-Champaign who led the research with U. of I. biochemistry Ph.D. student Yiquan Wang; and Meng Yuan, a staff scientist at Scripps Research in La Jolla, California. From left, Ph.D. student Yiquan Wang, biochemistry professor Nicholas Wu and their colleagues developed a method to differentiate antibody targets based on their genetic sequences. Edit embedded media in the Files Tab and re-insert as needed. With enough data, scientists should be able to predict not only the virus an antibody will attack, but which features on the pathogen the antibody binds to, Wu said.

In its on-going campaign to reveal the inner workings of the Sar-CoV-2 virus, the U.S. Department of Energy's (DOE) Argonne National Laboratory is leading efforts to couple artificial intelligence (AI) and cutting-edge simulation workflows to better understand biological observations and accelerate drug discovery. Argonne collaborated with academic and commercial research partners to achieve near real-time feedback between simulation and AI approaches to understand how two proteins in the SARS-CoV-2 viral genome, nsp10 and nsp16, interact to help the virus replicate and elude the host's immune system. The team achieved this milestone by coupling two distinct hardware platforms: Cerebras CS-1, a processor-packed silicon wafer deep learning accelerator; and ThetaGPU, an AI- and simulation-enabled extension of the Theta supercomputer, housed at the Argonne Leadership Computing Facility, a DOE Office of Science User Facility. To enable this capability, the team developed Stream-AI-MD, a novel application of the AI method called deep learning to drive adaptive molecular dynamics (MD) simulations in a streaming manner. Data from simulations is streamed from ThetaGPU onto the Cerebras CS-1 platform to simultaneously analyze how the two proteins interact.

Graphene Composites has partnered with researchers at the University to test the efficacy of their new graphene ink, which can coat PPE and kill incoming viruses. The product includes ultra thin sheets of graphene molecules that capture SARS-CoV-2 particles. Silver nanoparticles float in and destroy its exterior shell. Instead of relying on only a physical barrier, what if scientists were to develop a substance capable of killing COVID-19's viral particles when they come in contact with personal protective equipment? And in cases where the virus evades these protections, what if programming software could give radiologists an extra set of eyes when diagnosing the disease?

The C3.ai Digital Transformation Institute has awarded six UC Berkeley faculty funding to use AI to mitigate the threat of COVID-19. Bottom row, from left: Karen Chapple, Teresa Head-Gordon and Jennifer Listgarten. Six UC Berkeley-led projects have won funding from the recently launched C3.ai Digital Transformation Institute to harness the power of artificial intelligence (AI) to combat the spread of COVID-19 and other emerging diseases. These wide-ranging research projects will use AI and machine learning tools to understand and reduce the threat posed by the SARS-CoV-2 virus in a variety of ways, from tracking the transmission dynamics of the virus in Mexico to speeding the discovery of small molecules that could one day serve as pharmaceutical treatments for the disease. The C3.ai Digital Transformation Institute, a research consortium established in March by enterprise AI software company C3.ai and headquartered at Berkeley and the University of Illinois at Urbana-Champaign, aims to mobilize AI, machine learning and the Internet of Things to transform societal-scale systems.